For patients with relapsing-remitting multiple sclerosis (RRMS), there are currently six approved medications that have been shown to alter the natural course of the disease. The approved medications include three beta interferon formulations, glatiramer acetate, natalizumab and mitoxantrone. Treating aggressive forms of RRMS and progressive disease forms of MS still presents a great challenge to neurologists. Intense immunosuppression has long been thought to be the only feasible therapeutic option. In patients with progressive forms of MS, lymphoid tissues have been detected in the central nervous system (CNS) that may play a critical role in perpetuating local inflammation. Agents that are currently approved for patients with MS have no or very limited bioavailability in the brain and spinal cord. In contrast, cyclophosphamide (CYC), an alkylating agent, penetrates the blood-brain barrier and CNS parenchyma well. However, while CYC has been used in clinical trials and off-label in clinical practice in patients with MS for over three decades, data on its efficacy in very heterogeneous groups of study patients have been conflicting. New myeloablative treatment paradigms with CYC may provide a therapeutic option in patients that do not respond to other agents. In this article we review the scientific rationale that led to the initial clinical trials with CYC. We will also outline the safety, tolerability and efficacy of CYC and provide neurologists with guidelines for its use in patients with MS and other inflammatory disorders of the CNS, including neuromyelitis optica (NMO). Finally, an outlook into relatively novel treatment approaches is provided.
Balshov, K.E., Smith, D.R., Khoury, S.J., Hafler, D.A. and Weinrer, H.L. ( 1997) Increased interleukin-12 production in progressive multiple sclerosis: induction by activated CD4+ T cells via CD40 ligand. Proc Natl Acad Sci USA94: 599-603.
2.
Blake, D.A., Heller, R.H., Hsu, S.H. and Schacter, B.Z. ( 1976) Return of fertility in a patient with cyclophosphamide-induced azoospermia. Johns Hopkins Med J139: 20-22.
3.
Blumenfeld, Z. ( 2007) Gender difference: fertility preservation in young women but not in men exposed to gonadotoxic chemotherapy. Minerva Endocrinol32: 23-34.
4.
CAMMS223 Trial Investigators, Coles, A.J., Compston, D.A., Selmaj, K.W., Lake, S.L., Moran, S., Margolin, D.H. et al. (2008 ) Alemtuzumab vs. interferon beta-1a in early multiple sclerosis . N Engl J Med359: 1786-1801.
5.
Canadian Cooperative Multiple Sclerosis Study Group. ( 1991) The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. Lancet337: 441-446.
6.
Chet, J.T., Collins, D.L., Atkins, H.L., Freedman, M.S., Galal, A. and Arnold, D.L. ( 2006) Brain atrophy after immunoablation and stem cell transplant in multiple sclerosis. Neurology66: 1935-1937.
7.
Coles, A.J., Cox, A., Le Page, E., Jones, J., Trip, S.A., Deans, J. et al. (2006) The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol253: 98-108.
8.
Comabella, M., Balashov, K., Hafler, D.A., Issazadeh, S., Smith, D., Weiner, H.L. et al. (1998) Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy. J Clin Invest102: 671-678.
9.
Compendium of Pharmaceuticals and Specialties. ( 2006) ®Cytoxan: Canadian Pharmacists Association (Canada).
10.
Cree, B. ( 2006) Emerging monoclonal antibody therapies for multiple sclerosis . Neurologist12: 171-178.
11.
Cross, A.H., Stark, J.L., Lauber, J., Ramsbottom, M.J. and Lyons, J.A. ( 2006) Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol180: 63-70.
12.
Crowe, J.S., Hall, V.S., Smith, M.A., Cooper, H.J. and Tite, J.P. ( 1992) Humanized monoclonal antibody CAMPATH-1H: myeloma cell expression genomic constructs nucleotide sequence of cDNA constructs and comparison of effector mechanisms of myeloma and Chinese hamster ovary cell-derived material . Clin Exp Immunol87: 105-110.
13.
de Bittencourt, P.R. and Gomes-da-Silva, M.M. ( 2005) Multiple sclerosis: long-term remission after a high dose of cyclophosphamide. Acta Neurol Scand111: 195-198.
14.
De Ridder, D., van Poppel, H., Demonthy, L., D’hooghe, B., Gonsette, R., Carton, H. et al. (1998) Bladder cancer in patients with multiple sclerosis treated with cyclophosphamide. J Urol159: 1881-1884.
15.
Drachman, D.B., Jones, R.J. and Brodsky, R.A. ( 2003) Treatment of refractory myasthenia: ‘rebooting’ with high-dose cyclophosphamide. Ann Neurol53: 29-34.
16.
Drachman, D.B., Adams, R.N., Hu, R., Jones, R.J. and Brodsky, R.A. ( 2008) Rebooting the immune system with high-dose cyclophosphamide for treatment of refractory myasthenia gravis. Ann N Y Acad Sci1132: 305-314.
17.
Fassas, A., Passweg, J.R., Anagnostopoulos, A., Kazis, A., Kozak, T., Havrdova, E. et al. (2002) Hematopoietic stem cell transplantation for multiple sclerosis: a retrospective multicenter study. J Neurol249: 1088-1097.
Freedman, M.S., Atkins, H.L., Arnold, D.L. and Bar-Or, A. on behalf of the Canadian BMT group (2007) Immune ablation and autologous stem cell transplantation for aggressive multiple sclerosis: interim 5-year report. Mult Scler13(Suppl 2): 22(abstr).
20.
Gauthier, S.A. and Weiner, H.L. ( 2005) Cyclophosphamide therapy for MS. Int MS J. 12: 52-58.
21.
Gladstone, D.E., Golightly, M.G. and Brannagan, IIIT.H. ( 2007) High dose cyclophosphamide preferentially targets naïve T (CD45/CD4/RA+) cells in CIDP and MS patients. J Neuroimmunol190: 121-126.
22.
Gladstone, D.E., Zamkoff, K.W., Krupp, L., Peyster, R., Sibony, P., Christodoulou, C. et al. (2006) Highdose cyclophosphamide for moderate to severe refractory multiple sclerosis. Arch Neurol63: 1388-1393.
23.
Gobbini, M.I., Smith, M.E., Richert, N.D., Frank, J.A. and McFarland, H.F. ( 1999) Effect of open label pulse cyclophosphamide therapy on MRI measures of disease activity in five patients with refractory relapsing-remitting multiple sclerosis. J Neuroimmunol99: 142-149.
24.
Hartung, H.P., Gonsette, R., Konig, N., Kwiecinski, H., Guseo, A., Morrissey, S.P. et al. (2002) Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multi-centre trial. Lancet360: 2018-2025.
25.
Hauser, S.L., Dawson, D.M., Lehrich, J.R., Beal, M.F., Kevy, S.V., Propper, R.D. et al. (1983) Intensive immunesuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N Engl J Med308: 173-180.
26.
Hemmer, B. and Stuve, O. ( 2007) Revised criteria for neuromyelitis optica - a new diagnostic standard? Nat Clin Pract Neurol3: 132-133.
27.
Hohol, M.J., Olek, M.J., Orav, E.J., Stazzone, L., Hafler, D.A., Khoury, S.J. et al. (1999) Treatment of progressive multiple sclerosis with pulse cyclophosphamide/methylprednisolone: response to therapy is linked to the duration of progressive disease. Mult Scler5: 403-409.
28.
Hommes, O.R., Prick, J.J. and Lamers, K.J. ( 1975) Treatment of chronic progressive form of multiple sclerosis with a combination of cyclophosphamide and prednisone. Clin Neurol Neurosurg78: 59-72.
29.
Inglese, M., Mancardi, G.L., Pagani, E., Rocca, M.A., Murialdo, A., Saccardi, R. et al. (2004) Brain tissue loss occurs after suppression of enhancement in patients with multiple sclerosis treated with autologous haematopoietic stem cell transplantation. J Neurol Neurosurg Psychiatry75: 643-644.
30.
Khan, O.A., Zavartau-Hind, M., Caon, C., Din, M.U., Cochran, M., Lisak, D. et al. (2001) Effect of monthly intravenous cyclophosphamide in rapidly deteriorating multiple sclerosis patients resistant to conventional therapy. Mult Scler7: 185-188.
31.
Kanter, I.C., Huttner, H.B., Staykov, D., Biermann, T., Struffert, T., Kerling, F. et al. (2008) Cyclophosphamide for anti-GAD antibody-positive refractory status epilepticus. Epilepsia49: 914-920.
32.
Karni, A., Balashov, K., Hancock, W.W., Bharanidharan, P., Abraham, M., Kohoury, S.J. et al. (2004) Cyclophosphamide modulates CD4+ T cells into a T helper type 2 phenotype and reverses increased IFN-γ production of CD8+ T cells in secondary progressive multiple sclerosis. J Neuroimmunol146: 189-198.
33.
Kim, Y.H., Choi, B.K., Oh, H.S., Kang, W.J., Mittler, R.S. and Kwon, B.S.(2009) Mechanisms involved in synergistic anti-cancer effects of anti 4-1-BB and cyclophosphamide therapy. Mol Cancer Ther8: 469-478.
34.
Kovarsky, J. ( 1983) Clinical pharmacology and toxicology of Cyclophosphamide: emphasis on use in rheumatic diseases. Semin Arthritis Rheum12: 359-372.
35.
Krishnan, C., Kaplin, A.I., Brodsky, R.A., Drachman, D.B., Jones, R.J., Pham, D.L. et al. (2008) Reduction of disease activity and disability with highdose cyclophosphamide in patients with aggressive multiple sclerosis . Arch Neurol65: 1044-1051.
36.
Kurtzke, J.F. ( 1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology33: 1444-1452.
37.
La Mantia, L., Eoli, M., Salmaggi, A., Torri, V. and Milanese, C. ( 1998) Cyclophosphamide in chronic progressive multiple sclerosis: a comparative study. Ital J Neurol Sci19: 32-36.
38.
Lebrun, C., Debouverie, M., Vermersch, P., Clavelou, P., Rumbach, L., de Seze, J. et al. (2008) Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosis. Mult Scler14: 399-405.
39.
Likosky, W.H., Fireman, B., Elmore, R., Eno, G., Gale, K., Goode, G.B. et al. (1991) Intense immunosuppression in chronic progressive multiple sclerosis: the Kaiser study. J Neurol Neurosurg Psychiatry54: 1055-1060.
40.
Lublin, F.D. and Reingold, S.C. ( 1996) Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis . Neurology46: 907-911.
41.
Makhani, M.P., Gorman, H.M., Branson, L., Stazzone, B.L., Banwell, T. and Chitnis. (2009) Cyclophosphamide therapy in pediatric multiple sclerosis. Neurology72: 2076-2082.
42.
Masala, A., Faedda, R., Alagna, S., Satta, A., Chiarelli, G., Rovasio, P.P. et al. (1997) Use of testosterone to prevent cyclophosphamide-induced azoospermia. Ann Intern Med126: 292-295.
43.
Meirow, D., Epstein, M., Lewis, H., Nugent, D. and Gosden, R.G. ( 2001) Administration of cyclophosphamide at different stages of follicular maturation in mice: effects on reproductive performance and fetal malformations. Hum Reprod16: 632-637.
Oger, J. ( 2007) Immunosuppression: promises and failures. J Neurol Sci259: 74-78.
46.
ONS Clinical Practice Committee. (1999) Cancer Chemotherapy Guidelines and Recommendations for Practice. Pittsburgh, PA: ONS, pp. 32-41.
47.
Patti, F., Reggio, E., Palermo, F., Fiorilla, T., Politi, G., Nicoletti, A. et al. (2004) Stabilization of rapidly worsening multiple sclerosis for 36 months in patients treated with interferon beta plus cyclophosphamide followed by interferon beta. J Neurol251: 1502-1506.
48.
Perini, P., Calabrese, M., Rinaldi, L. and Gallo, P. ( 2007) The safety profile of cyclophosphamide in multiple sclerosis therapy. Expert Opin Drug Saf6: 183-190.
49.
Perini, P. and Gallo, P. ( 2003) Cyclophosphamide is effective in rapidly deteriorating secondary progressive multiple sclerosis. J Neurol250: 834-838.
50.
Polman, C.H., Reingold, S.C., Edan, G., Filippi, M., Hartung, H.P., Kappos, L. et al. (2005) Diagnostic criteria for multiple sclerosis: 2005 revisions to the ‘McDonald Criteria’. Ann Neurol58: 840-846.
51.
Portaccio, E., Siracusa, G., Piacentini, S., Sorbi, S. and Amato, M.P. ( 2003) Safety and tolerability of cyclophosphamide ‘pulses’ in multiple sclerosis: a prospective study in a clinical cohort. Mult Scler9: 446-450.
52.
Poser, C.M., Party, D.W., Scheinberg, L., McDonald, W.I., Davis, F.A., Ebers, G.C. et al. (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol13: 227-231.
53.
Prineas, J.W. ( 1979) Multiple sclerosis: presence of lymphatic capillaries and lymphoid tissue in the brain and spinal cord. Science203: 1123-1125.
54.
Prineas, J.W. and Wright, R.G. ( 1978) Macrophages, lymphocytes, and plasma cells in the perivascular compartment in chronic multiple sclerosis. Lab Invest38: 409-421.
55.
Radis, C.D., Kahl, L.E., Baker, G.L., Wasko, M.C., Cash, J.M., Gallatin, A. et al. (1995) Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year follow up study. Arthritis Rheum38: 1120-1127.
56.
Roccatagliata, L., Rocca, M.A., Valsasina, P., Bonzano, L., Sormani, M., Saccardi, R. et al. (2007) The long-term effect of AHSCT on MRI measures of MS evolution: a five year follow-up study. Mult Scler13: 1068-1070.
57.
Saccardi, R., Kozak, T., Bocelli-Tyndall, C., Fassas, A., Kazis, A., Havrdova, E. et al. (2006) Autologous stem cell transplantation for progressive multiple sclerosis: Update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database. Mult Scler12: 814-823.
58.
Schwartzman, R.J., Simpkins, N., Alexander, G.M., Reichenberger, E., Ward, K., Lindenberg, N. et al. (2009) High-dose cyclophosphamide in the treatment of multiple sclerosis. CNS Neurosci Ther15: 118-127.
59.
Smith, D.R. ( 2005) Cyclophosphamide therapy for multiple sclerosis . In: Olek, M.J. (ed.). Multiple SclerosisHumana Press: New York , pp. 171-191.
60.
Smith, D.R., Balashov, K.E., Hafler, D.A., Khoury, S.J. and Weiner, H.L. ( 1997) Immune deviation following pulse cyclophosphamide/methylprednisolone treatment of multiple sclerosis: increased interleukin-4 production and associated eosinophilia. Ann Neurol42: 313-318.
61.
Smith, D.R., Weinstock-Guttman, B., Cohen, J.A., Wei, X., Gutmann, C., Bakshi, R. et al. (2005) A randomized blinded trial of combination therapy with cyclophosphamide in patients with active multiple sclerosis on interferon beta. Mult Scler11: 573-582.
62.
Steinman, L. ( 2001) Multiple sclerosis: a two-stage disease. Nat Immunol2: 762-764.
63.
Stuve, O., Cravens, P.D., Frohman, E.M., Phillips, J.T., Remington, G.M., von Geldern, G. et al. (2009) Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy. Neurology72: 396-401.
64.
Stuve, O., Marra, C.M., Jerome, K.R., Cook, L., Cravens, P.D., Cepok, S. et al. (2006) Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol59: 743-747.
65.
Takamoto, S., Sakura, N., Namera, A. and Yashiki, M. ( 2004) Monitoring of urinary acrolein concentration in patients receiving cyclophosphamide and ifosphamide. J Chromatogr B Analyt Technol Biomed Life Sci806: 59-63.
66.
Takashima, H., Smith, D.R., Fukaura, H., Khoury, S.J., Hafler, D.A. and Weiner, H.L. ( 1998) Pulse cyclophosphamide plus methylprednisolone induces myelin-antigen-specific IL-4 secreting T cells in multiple sclerosis patients . Clin Immunol Immunopathol88: 28-34.
67.
Talar-Williams, C., Hijazi, Y.M., Walther, M.M., Linehan, W.M., Hallahan, C.W., Lubensky, I. et al. (1996) Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med124: 477-484.
68.
Tamir, S. and Tannenbaum, S.R. ( 1996) The role of nitric oxide (NO.) in the carcinogenic process . Biochim Biophys Acta1288: F31-36.
69.
Ujházy, E., Balonová, T., Durisová, M., Gajdosík, A., Jansák, J. and Molnárová, A. ( 1993) Teratogenicity of cyclophosphamide in New Zealand white rabbits. Neoplasma40: 45-49.
70.
Weiner, H.L., Mackin, G.A., Orav, E.J., Hafler, D.A., Dawson, D.M., LaPierre, Y. et al. (1993) Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group. Neurology43: 910-918.
71.
Weinstock-Guttman, B. ( 1997) Treatment of fulminant multiple sclerosis with intravenous cyclophosphamide. The Neurologist3: 178-185.
72.
Wetzels, J.F.M. ( 2004) Cyclophosphamide-induced gonadal toxicity: a treatment dilemma in patients with lupus nephritis. Neth J Med62: 347-352.
73.
Zephir, H., de Seze, J., Duhamel, A., Debouverie, M., Hautecoeur, P., Lebrun, C. et al. (2004) Treatment of progressive forms of multiple sclerosis by cyclophosphamide: a cohort study of 490 patients. J Neurol Sci218: 73-77.
74.
Zipoli, V., Portaccio, E., Hakiki, B., Siracusa, G., Sorbi, S. and Amato, M.P. ( 2008) Intravenous mitoxantrone and cyclophosphamide as second-line therapy in multiple sclerosis: An open-label comparative study of efficacy and safety. J Neurol Sci266: 25-30.
75.
Zivadinov, R., Reder, A.T., Fillippi, M., Minagar, A., Stüve, O., Lassmann, H. et al. (2008) Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis. Neurology71: 136-144.
